Global Startup Funding Watch

Late-Stage Funding Dominance and Global Market Dynamics

Late-Stage Funding Dominance and Global Market Dynamics

Key Questions

What is Roche's acquisition of PathAI?

Roche acquired PathAI for $750 million upfront (up to $1.05 billion total) to advance AI-powered digital pathology and precision oncology. It extends their 2021 partnership.

What other AI biotech deals occurred?

Anthropic invested $400 million in Coefficient Bio, signaling big pharma's acceleration in AI diagnostics and healthtech integration.

Why is big pharma pursuing AI health acquisitions?

Acquisitions like Roche-PathAI and Anthropic-Coefficient Bio reflect pharma's push to integrate AI for diagnostics, pathology, and precision medicine advancements.

K-shaped market: 91% of US VC in $100M+ rounds, AI captures 86% US VC. European AI surge (UK funding up 102%, Mistral, SoftBank €75B). China IPO pressure (DeepSeek $70.8B target). Fintech M&A (Bloomberg-Canoe, Legora-Wexler). Global M&A Q2 $324B disclosed. Corporate VC via VCaaS model.

Sources (4)
Updated Jul 29, 2026
What is Roche's acquisition of PathAI? - Global Startup Funding Watch | NBot | nbot.ai